This Article Full Text (PDF) Other Versions of this Article: AAC.00766-06v1 50/11/3543    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lounis, N. Articles by Jarlier, V. Search for Related Content PubMed PubMed Citation Articles by Lounis, N. Articles by Jarlier, V.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00766-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Combinations of R207910 with drugs used to treat MDR-TB have the potential to shorten treatment duration

Laboratoire de Bactériologie, Faculté de Médecine Pitié-Salpêtrière, and Centre National de Référence de la Résistance des Mycobactéries aux Antituberculeux, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie Paris 6, Paris, France.; Tibotec Pharmaceuticals Ltd, Johnson and Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium

^* To whom correspondence should be addressed. Email: kandries{at}prdbe.jnj.com,

	Abstract

The objective of the present study was to identify the optimal R207910-containing regimen to administer to patients who cannot receive rifampin (RIF) and isoniazid (INH) because of multidrug resistant tuberculosis (MDR-TB), concomitant use of antiretroviral drugs or toxicity.

Mice were infected intravenously with 5x10⁶ CFU of the H37Rv strain and treated 5x/week with R207910 alone, or various combinations of R207910 with the second line drugs amikacin (AMK), pyrazinamide (PZA), moxifloxacin (MXF) and ethionamide (ETH).

All R207910-containing regimens were significantly more active than the non-R207910 containing regimens after one month of therapy. When given for 2 months, R207910 alone was more active than the WHO standard first line regimen RIF-INH-PZA. When combined with second line drugs, the combinations were more active than the current recommended regimen for MDR-TB AMK-ETH-MXF-PZA and culture negativity of the both lungs and spleens was reached after 2 months of treatment in almost every case.

This article has been cited by other articles:

• Rustomjee, R., Diacon, A. H., Allen, J., Venter, A., Reddy, C., Patientia, R. F., Mthiyane, T. C. P., De Marez, T., van Heeswijk, R., Kerstens, R., Koul, A., De Beule, K., Donald, P. R., McNeeley, D. F. (2008). Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 52: 2831-2835 [Abstract] [Full Text]  
• Lounis, N., Gevers, T., Van Den Berg, J., Verhaeghe, T., van Heeswijk, R., Andries, K. (2008). Prevention of Drug Carryover Effects in Studies Assessing Antimycobacterial Efficacy of TMC207. J. Clin. Microbiol. 46: 2212-2215 [Abstract] [Full Text]  
• Lenaerts, A. J., Hoff, D., Aly, S., Ehlers, S., Andries, K., Cantarero, L., Orme, I. M., Basaraba, R. J. (2007). Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910. Antimicrob. Agents Chemother. 51: 3338-3345 [Abstract] [Full Text]  
• Ibrahim, M., Andries, K., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V., Veziris, N. (2007). Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis. Antimicrob. Agents Chemother. 51: 1011-1015 [Abstract] [Full Text]